Congratulations to Stem Pharm – a CTC client, SBIR Advance awardee and Wisconsin Innovation Award winner – on their recently announced collaboration to develop a disease model to validate novel targets identified by Verge Genomics for Parkinson’s disease (PD).
Stem Pharm is a neurological drug discovery platform company that applies its proprietary 3D human neuro-immune organoids and biomaterials to the discovery and validation of new neurological disease targets and therapeutics.
Steven Visuri, CEO of Stem Pharm, said of the partnership, “Verge’s all-in-human approach to drug discovery aligns perfectly with our ideology, and by combining our strengths and resources, we aim to establish a state-of-the-art Parkinson’s disease model. This collaboration represents a significant step forward in our collective mission to discover transformative therapies for patients suffering from this debilitating disease.”
Stem Pharm has most recently received Phase I and Phase II awards from NIH SBIR/STTR program which led them to CTC’s SBIR Advance program for each Phase.
“Stem Pharm has been successfully funded by the NIH to develop products related to neurological diseases like Alzheimer’s Disease and Glioblastoma,” said Todd Strother, SBIR Advance Program Manager. “We are happy to have provided SBIR Advance funds for both their Phase I and Phase II SBIR projects. These SBIR Advance funds assist in commercialization and business activities to help bring these important products to fruition. Stem Pharm is gaining traction and recognition for their work in neurological diseases and it is exciting to see their growth and successes. CTC is excited to be part of Stem Pharm’s journey!”
Find out more about this collaboration in the BioSpace coverage from October 10.
If you have already received an SBIR Phase I or II grant, apply by Oct. 17 for an SBIR Advance Match Grant and mentoring. If you have an innovative idea that you hope to get funded, request CTC consulting now!
